Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey - Top-Institutions - MDSpire

Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey

  • By

  • Jack W McHugh

  • Larry M Baddour

  • Supavit Chesdachai

  • Susan E Beekmann

  • Philip M Polgreen

  • Walter R Wilson

  • Daniel C DeSimone

  • September 15, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Infectious Diseases
    • Cardiology
    • Clinical Research

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Clinical Trials
    • Epidemiology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Cardiology
    • Clinical Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Clinical Research
    • Antimicrobial Stewardship

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Infectious Diseases
    • Cardiology
    • Clinical Research

Original Source(s)

Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey

  • by Jack W McHugh, Larry M Baddour, Supavit Chesdachai, Susan E Beekmann, Philip M Polgreen, Walter R Wilson, Daniel C DeSimone

  • September 15, 2025

Related Content

Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Nangarhar, Afghanistan

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis